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be achieved. Total discounted costs in 23.5 years were 557 766.80 PLN (1EURO3.96
PLN) for patients subjected to 200 days prophylaxis and 542 509.92 PLN for patients
subjected to 110 days prophylaxis. The incremental cost-effectiveness ratio (ICER)
was 39,669 PLN and cost-utility ratio (ICUR) 48,008 PLN. Sensitivity analysis con-
firmed the base case analysis results. The results were sensitive only to the time
horizon assumed (when time horizon was shorter than 4 years ICER/ICUR were
above the accepted 110,000 PLN cost-effectiveness threshold). CONCLUSIONS: The
prolongation of CMV disease prophylaxis in kidney transplant recipients from 110
to 200 days is highly cost-effective from Polish payer perspective.
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OBJECTIVES: This study will evaluate lifetime cost-utility of a therapy based on
lopinavir/ritonavir vs atazanavir ritonavir, using a tenofovir-emtricitabine back-
bone, in an Italian cohort of HIV infected anti-retroviral-naïve patients. An inter-
national literature review revealed, that there are limited useful data to inform
Italian decision makers, taking into consideration Country specific costs and
utility. METHODS: Starting from the Broder (2011) Markov microsimulation model
and CASTLE study data, an Italian model was developed to specify direct costs and
health outcomes from Italian HIV-infected patients and their treatment, adopting
a national health service (NHS) payer perspective. The Health State (HS) transition
probabilities were assessed within a sample of 319 patients on treatment within
the Lombardy Region (the probability vector took into consideration the results of
the 96-week CASTLE trial, the principal published literature and the evidence re-
lated to the Italian population in terms of cholesterol changes, coronary heart
disease (CHD) events and adverse events (AEs). Costs related to AEs and to the care
of HIV patients were correlated to clinical effectiveness data, as well as institu-
tional indications, protocols and reimbursement tariff of hospitals located in Lom-
bardy Region. RESULTS: The newly developed Italian Markov model consisting of 8
HS, informs about the distribution of the Italian population, and forecasting the
evolution of the clinical pathway of anti-retroviral-naïve patients through different
stages up to death. Clinical effectiveness and absorption of resources were inves-
tigated to truly represent the Italian HIV context. CONCLUSIONS: The innovative
method of this Markov model construction based on national data, ensures the
opportunity of a closer results alignment to specific Italian costs, and to its usability
from an Italian decision making and payer’s perspective.
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OBJECTIVES: Every year 5-25% of the world’s population suffers from influenza.
Influenza and ILI (influenza like illness) among working adults are responsible for
the enhanced sickness absenteeism, limited work capacity and efficiency, as well
as for the increased health service demand. The aim of this pilot study was to
estimate the indirect cost of influenza and ILI (both absenteeism and presenteeism)
from emloper’s perspective. METHODS: Data was collected from Polish citizens in
working age, who were employed at the time of collecting data. Human Capital
Approach method was used in quantifying costs. Modified version of Work Produc-
tivity and Activity Impairment General Health questionnaire was used to estimate
absenteeism and presenteeism in the population. Responders were questioned
about the period from the first day of January 2011 to the day of the questionnaire
completion, which represents the period when the highest ILI incidence rate. The
results of the questionnaire were extrapolated for the whole year of 2011. The
indirect costs were calculated on the basis of the average gross wage value in the
corporate sector in 2011, which amounts to 911 EUR (1 EUR3.95 PLN). RESULTS:
The final population comprised 134 employees (average age 31 years, 56.7% men).
Immunized against influenza were 23.1% of the people who participated in the
study. 53.7% of all respondents reported that during the investigation period had
influenza or influenza-like symptoms. The productivity loss at workplace due to
illness was estimated at 4.0% (3,2 vs. 4,2, Immunized vs. non-immunized, respec-
tivetly; p0,44). Estimated absenteeism equaled 2.2% (1,7 vs 2,4, Immunized vs
non-immunized, respectively; p0,88).CONCLUSIONS: Indirect costs of productiv-
ity loss due to influenza and ILI are substantial to Polish economy. Due to the
relatively small non-representative population results should be treated with cau-
tion.
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OBJECTIVES: To assess adherence to treatment for HCV monoinfected and HCV/
HIV co-infected patients, interim analysis at 12 weeks after therapy initiation.
METHODS: Observational, prospective study performed by 120 investigators in
Spain. Patients were hepatitis C (HCV) monoinfected or HCV/HIV co-infected, 18
years and naïve to HCV treatment. Visits were at treatment initiation (baseline), 4,
12, and every 24 weeks during HCV therapy and 24 weeks after finalization; only
interim results up to wk12 are presented. Each visit assessed adherence by Ad-
hepta and Morinsky-Green questionnaires. Adhepta questionnaire includes two
questions related to treatment adherence and 11 (monoinfected) or 13 (co-infected)
questions about reasons for non-adherence; non-adherence to treatment was as-
sessed following the 80/80/80 rule (not administered any HCV drug on 20% of the
occasions). RESULTS: Evaluable patients were 1,120, 801 monoinfected (68.3%
male) and 319 co-infected (74.9% male). Mean (SD) age was 45.3 (8.8) years. Non-
adherent patients by Adhepta were 2.5% and 3.5% for monoinfected at wk4 and
wk12, respectively; and 2.7% and 2.5% patients, among co-infected. No differences
between study groups were observed. Non-adherent patients by Morisky-Green
were 14.0% and 14.8% at wk4, and wk12, respectively for monoinfected; and 23.3%
and 23.2% for co-infected. Monoinfected patients were more adherent to treatment
than co-infected patients at wk4 and wk12 (p0.05). Assessed by Adhepta ques-
tionnaire, non-adherence most common reason reported was ‘forgetting to take
the drug’ (8.2% monoinfected and 10.8% co-infected).CONCLUSIONS:Adherence to
treatment remains constant through 12 weeks after treatment initiation. Differ-
ences in treatment adherence observed between both questionnaires must be
compared at the end of the HCV treatment and analysing their correlation with
patient self-reported medication record.
PIN87
HEPATITIS C TREATMENT CONTINUATION RATES IN TREATMENT-NAÏVE
GENOTYPE 1 PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Mussolino F1, Vaz P1, Morais AD2, Pereira ML2
1NEW BD - Business Developers, São Paulo, SP, Brazil, 2Janssen Cilag Farmaceutica, São Paulo,
SP, Brazil
OBJECTIVES:Determine real-life treatment continuation rates of chronic Hepatitis
C (HCV) treatment from a database of medicine dispensation in the Brazilian public
healthcare system. METHODS: Monthly data from a public database of medicine
dispensation was analyzed for a period of 17 months. The patient cohort was
defined as all new HCV (CID10 B18.2) patients initiating treatment between January
and December 2009. To identify HCV genotype 1 (G1) patients, it was assumed G1
patients initiated treatment with the pegylated forms of the interferons (pegIFN),
as defined by the Brazillian national guidelines for HCV. RESULTS: Between Janu-
ary and December 2009, 10,992 patients began treatment for HCV. Around 58% of
these patients were male with a median age of 49.7 years. Of these, 82% of patients
(9,019) were considered G1 as they began treatment with pegIFN and/or ribavirin.
Almost all patients (97%) began treatment with the treatment combination pegIFN
and ribavirin, with an equal split among both brands of pegIFN. For all HCV patients
treatment mean/median was 38,3/40 weeks compared to 40.2/44.0 weeks for G1
patients. At week 48, 63% of all HCV patients had discontinued treatment com-
pared to 58% of G1 patients. At week 24, around 19% of all HCV patients had
discontinued treatment compared to 18% of G1 patients. The maximum observed
treatment duration was 85 weeks in both all HCV and G1 patients. CONCLUSIONS:
Discontinuation rates before week 24 were similar between all HCV and G1 pa-
tients. Although 48 weeks of treatment is the established duration for G1 patients,
the majority of patients discontinue treatment earlier. These data, however, do not
guarantee patients actually receive treatment, as it follows medicine dispensation.
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OBJECTIVES: Immunization dose was considered as a late immunization dose if it
was administered after the recommended age. The aims of this study are to deter-
mine the frequency and percent of this type of doses among child immunization
schedule, and to determine the number of late immunization dose received by
each child.METHODS:Data was collected retrospectively from 528 children immu-
nization cards in Iraq to obtain the immunization history of each individual child.
This study was restricted the analyses to the vaccines administered before age 2
years. Each children must received seven doses at seven times, every dose consist
of many types of vaccines. RESULTS: More than 63% of late immunization doses
were shown in the third dose (OPVDTP) at fourth month of child life. Hundred and
forty five children were immunized with four late immunization doses out of seven
immunization doses, and 1.5% of children were immunized with 7 late immuniza-
tion doses. CONCLUSIONS: This study found that compliance with WHO immuni-
zation recommendations is low and inappropriate immunization doses were occur
frequently, and leading to incomplete or partial immunization compliance. With
an increase in parent’s knowledge of immunization guidelines against infectious
agents, it is very important to implement strategies that will lead to improved and
developed immunization practice and childhood immunization coverage in the
future.
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